277 related articles for article (PubMed ID: 10741861)
1. Interleukin 12 and innate molecules for enhanced mucosal immunity.
Boyaka PN; Lillard JW; McGhee J
Immunol Res; 1999; 20(3):207-17. PubMed ID: 10741861
[TBL] [Abstract][Full Text] [Related]
2. Cytokines as adjuvants for the induction of mucosal immunity.
Boyaka PN; McGhee JR
Adv Drug Deliv Rev; 2001 Sep; 51(1-3):71-9. PubMed ID: 11516780
[TBL] [Abstract][Full Text] [Related]
3. IL-12 is an effective adjuvant for induction of mucosal immunity.
Boyaka PN; Marinaro M; Jackson RJ; Menon S; Kiyono H; Jirillo E; McGhee JR
J Immunol; 1999 Jan; 162(1):122-8. PubMed ID: 9886377
[TBL] [Abstract][Full Text] [Related]
4. Lymphotactin acts as an innate mucosal adjuvant.
Lillard JW; Boyaka PN; Hedrick JA; Zlotnik A; McGhee JR
J Immunol; 1999 Feb; 162(4):1959-65. PubMed ID: 9973465
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins.
Lillard JW; Boyaka PN; Chertov O; Oppenheim JJ; McGhee JR
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):651-6. PubMed ID: 9892688
[TBL] [Abstract][Full Text] [Related]
6. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
Marinaro M; Boyaka PN; Jackson RJ; Finkelman FD; Kiyono H; Jirillo E; McGhee JR
J Immunol; 1999 Jan; 162(1):114-21. PubMed ID: 9886376
[TBL] [Abstract][Full Text] [Related]
7. RANTES potentiates antigen-specific mucosal immune responses.
Lillard JW; Boyaka PN; Taub DD; McGhee JR
J Immunol; 2001 Jan; 166(1):162-9. PubMed ID: 11123289
[TBL] [Abstract][Full Text] [Related]
8. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses.
Marinaro M; Boyaka PN; Finkelman FD; Kiyono H; Jackson RJ; Jirillo E; McGhee JR
J Exp Med; 1997 Feb; 185(3):415-27. PubMed ID: 9053442
[TBL] [Abstract][Full Text] [Related]
9. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
[TBL] [Abstract][Full Text] [Related]
10. Mucosal immunity: regulation by helper T cells and a novel method for detection.
Jackson RJ; Marinaro M; VanCott JL; Yamamoto M; Okahashi N; Fujihashi K; Kiyono H; Chatfield SN; McGhee JR
J Biotechnol; 1996 Jan; 44(1-3):209-16. PubMed ID: 8717406
[TBL] [Abstract][Full Text] [Related]
11. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity.
Boyaka PN; Marinaro M; Jackson RJ; van Ginkel FW; Cormet-Boyaka E; Kirk KL; Kensil CR; McGhee JR
J Immunol; 2001 Feb; 166(4):2283-90. PubMed ID: 11160283
[TBL] [Abstract][Full Text] [Related]
12. Nasal immunization with the 40-kDa outer membrane protein of Porphyromonas gingivalis plus cholera toxin induces protective immunity in aged mice.
Cai Y; Kurita-Ochiai T; Kobayashi R; Hashizume T; Yamamoto M
J Oral Sci; 2013; 55(2):107-14. PubMed ID: 23748449
[TBL] [Abstract][Full Text] [Related]
13. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity.
Ohmura-Hoshino M; Yamamoto M; Yuki Y; Takeda Y; Kiyono H
Vaccine; 2004 Sep; 22(27-28):3751-61. PubMed ID: 15315856
[TBL] [Abstract][Full Text] [Related]
14. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues.
Xu-Amano J; Kiyono H; Jackson RJ; Staats HF; Fujihashi K; Burrows PD; Elson CO; Pillai S; McGhee JR
J Exp Med; 1993 Oct; 178(4):1309-20. PubMed ID: 8376936
[TBL] [Abstract][Full Text] [Related]
15. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella.
VanCott JL; Staats HF; Pascual DW; Roberts M; Chatfield SN; Yamamoto M; Coste M; Carter PB; Kiyono H; McGhee JR
J Immunol; 1996 Feb; 156(4):1504-14. PubMed ID: 8568254
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity.
Boyaka PN; Tafaro A; Fischer R; Fujihashi K; Jirillo E; McGhee JR
Curr Pharm Des; 2003; 9(24):1965-72. PubMed ID: 12871182
[TBL] [Abstract][Full Text] [Related]
17. MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity.
Lillard JW; Singh UP; Boyaka PN; Singh S; Taub DD; McGhee JR
Blood; 2003 Feb; 101(3):807-14. PubMed ID: 12393512
[TBL] [Abstract][Full Text] [Related]
18. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB.
Verma V; Tan W; Puth S; Cho KO; Lee SE; Rhee JH
J Transl Med; 2016 May; 14(1):135. PubMed ID: 27184355
[TBL] [Abstract][Full Text] [Related]
19. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues.
Imaoka K; Miller CJ; Kubota M; McChesney MB; Lohman B; Yamamoto M; Fujihashi K; Someya K; Honda M; McGhee JR; Kiyono H
J Immunol; 1998 Dec; 161(11):5952-8. PubMed ID: 9834076
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant.
Bielinska AU; O'Konek JJ; Janczak KW; Baker JR
Vaccine; 2016 Jul; 34(34):4017-24. PubMed ID: 27317451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
